All lobbying filings
Acadia Pharmaceuticals
Acadia Pharmaceuticals filed a Q1 report for Acadia Pharmaceuticals on April 18, 2025.
Lobbying for Acadia Pharmaceuticals
Filing · LD-2 quarterly report
Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 18, 2025
Expenses
$440,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
California
Government bodies contacted
2
Lobbying activity
3
Implementation of the Inflation Reduction Act of 2022; Orphan Cures Act (HR 946); National Plan to End Parkinsons Act (Public Law 118-66, 118th Congress); Give Kids A Chance (HR1262); Cameron's Law (HR1414).
Implementation of the Inflation Reduction Act of 2022; Issues related to protecting patient access to medicines in Medicare; Issues related to access to medicines for Parkinson's disease patients; Issues related to Antipsychotic use in Medicare; Orphan Cures Act (HR 946); National Plan to End Parkinsons Act (Public Law 118-66, 118th Congress); EPIC Act (HR 1492).
Cameron's Law (HR 14114)